Life Sciences Archive » October, 2018

Life Sciences - October, 2018

325 articles

• Allergan, Generic Cos. Battle Over Restasis Launch Plans
• Groundskeeper Accepts Slashed $78M Roundup Award
• Myriad Genetics Tries To Ditch Billing Fraud Stock Drop Suit
• Consumer Sent To Drawing Board On Tainted Drug Claims
• HHS Reverses Course, Will Start 340B Fines Soon
• Weil Gotshal Lawyers' Tough Tactics Sealed J&J Talc Win
• Pa. Appeals Court Upholds $2.5M Philly Risperdal Verdict
• Deals Rumor Mill: Athenahealth, CVC, Thermo Fisher
• 3 Health Care IPOs Net $390M Total To Close Choppy October
• Pharma Co. Egalet Hits Ch. 11 With $129M Debt
• Justice Alito Unrecuses Self From Merck's Fosamax Appeal
• US Narrows Bid For Israeli Court Docs In $163.5M Tax Row
• Judge Pauses Invalidation Of Patent For Janssen's Zytiga
• Boston Says Opioid Suit Is Purely A State Law Matter
• Israeli PE Firm Shavit Nabs $100M For Latest Fund
• Juul Labs Gets Some Claims Tossed In E-Cig Labeling Suit
• Why Current Laws Won't Protect Property Rights For DNA
• Tips For Drafting M&A Agreements After Akorn
• Assessing Innovations For Medical Device Development
• Genentech Sues Over Stolen Secrets; 4 Ex-Workers Indicted
• FCA Decision Tracker: Continued Interpretations Of Escobar
• DC Circ. Backs FDA Denial Of Rx-Only MiraLAX Generics
• Ex-Valeant Exec, Pharmacy CEO Get Year For Kickback Fraud
• Celgene Corp. Drug Buyers Denied Cert. In Antitrust Suit
• Akorn Says Chancery Rewrote Law In Letting $4.3B Deal Die
• Ill. AG Sues Sterigenics Alleging Pollution Problems
• Conflicting Verdict Sunk Lotion Trademark Row, 3rd Circ. Told
• Waxman Opposes Hatch Plan To Keep Generics Out Of PTAB
• Drs. Group Urges FTC Antitrust Scrutiny Of Insulin Pricing
• Amarin Says Supplement Cos. Can't Tout Its Omega-3 Trial
• Investor Attys Seek $8.5M In $43M Medtronic Stock-Drop Deal
• Defendants Can't Be Held To Impossible Discovery Standards
• Building The Regulatory Conversation On Cellular Agriculture
• Protecting Law Firm Talent At Both Ends
• Insurer Wants Out Of Covering Pharma Co. In Opioid Suits
• 23andMe's Counterclaims Trimmed In Insurance Dispute
• Perrigo Hit With Investors' Suit Over Thwarted Mylan Deal
• Judge Lets FTC Slip Allergan's Suit, But Rips Venue Conduct
• White & Case Leads EQT In $654M Karo Pharma Bid
• NJ Judge Invalidates Patent For Janssen Cancer Drug Zytiga
• Pharma Co. Gets Pneumonia Drug Stock-Drop Suit Tossed
• Supreme Court Won't Look At HIV Drug Patent Challenge
• Doc Must Get Share Of $3B GSK Settlement, NJ Court Says
• Endo Shareholders Fight Bid To Nix Generic Price-Fixing Suit
• Takeda Offers To Sell Shire Drug To Get EU's OK For Takeover
• Wendy Olson Talks Twin Falls, Tribes, Private Practice
• How SUPPORT Will Affect Pharma Interactions With DEA
• Solicitor General Asked To Weigh In On Roche Patent Appeal
• J&J Can't Arbitrate Distributor's Claims In Remicade Row
• 12 Firms To Guide Six IPOs Raising $468M Amid Dicey Market
• Mass. Priest Wants Out Of SEC's $1.3M Short-Selling Suit
• Teva's Off-Label Fentanyl Promotion Fueled Crisis, Ky. Says
• Only Loestrin Market Matters In Antitrust Row, Retailers Say
• Allergan, Tribe Want IPRs Blocked As They Turn To High Court
• Investor Seeks Records From Harbor Pharma Research Co.
• Pa. Man To Address Time Limit In Covidien Hernia Mesh Suit
• Abbott, AbbVie Pay $25M Over Off-Label Promos, Kickbacks
• Former Ice Miller Partner Rejoins Firm's Business Practice
• $400M Arbitral Award Against Czechs Isn't Binding: DC Circ.
• 11th Circ. Orders New Trial Over Incontinence IP Fraud
• Judging A Book: Brown Reviews 'Dangerous Leaders'
• Patent Dance Developments: A Tale Of 2 Antibodies
• Ropes & Gray Adds Ex-FDA Enforcement Pro In DC
• 5 Takeaways As Trump Eyes Cut To Medicare Drug Payments
• Valeant Poised To Pursue Label Suits Over IBS Drug Copycats
• USPTO Can't Pause Patent Fee Row To Mull High Court Bid
• L'Oréal Ex-VP Fired After Pointing Out Toxic Workplace: Suit
• Exxon, Chevron, Others Keep Gas Additive Suit In Fed. Court
• DOJ Unveils Appalachian Opioid Strike Force, $35M For Kids
• Biopharma Dodges Fund's Suit Alleging It Reneged On Shares
• Exforge Generic Deal Is Clear Antitrust Violation, Court Told
• Full Fed. Circ. Urged To Rehear 'Blocking Patents' Ruling
• A First Look At The Sweeping New Opioid Law
• Breaking The Rules: 3 Ways To 'Lead' A Direct Examination
• Trump Signs Vast Opioid Legislation Into Law
• Bressler Amery Launches Cannabis Practice In Fla., NJ
• Women's Expert Witnesses Axed In Bayer Mirena MDL
• Deals Rumor Mill: CommScope, Endeavor, Innovent
• Justices Told $200M Merck IP Award Should Be Reinstated
• Teva Asks FTC To Tweak Watson-Actavis Merger Fix
• Shkreli, Ex-Firm Hit With Antitrust Suit Over Kidney Drug
• NJ Law Applies In Bard Pelvic Mesh Multicounty Litigation
• J&J Unit Snags Win Over Glucose Test Strips Patent
• UK Probes Thermo Fisher's Buy Of Electron Microscope Co.
• Biogen Prevails In Fed. Circ. MS Drug Dispute With Forward
• EHealthline's Ex-JV Partners Beat Trade Secrets Suit
• A Closer Look At CMS' Drug Price Disclosure Proposal
• 1st Circ. Weighs In On Uninjured Class Members Issue
• From Medicine To Sexbots, AI Raises Liability Questions
• Gibson Dunn Steers $625M Sale Of Kraft Heinz India Brands
• Takeda Tries Again To Shake Actos Antitrust Claims
• FDA Warning Wire: Global Crackdown On Online Drug Sales
• CORRECTED: ICE's IP Unit Seizes Illegal, Unsafe Decorative Contact Lenses
• FDA Focus: What Loeb & Loeb's Practice Chair Is Watching
• Recycled Arguments Doom Piglet Vaccine Patent Challenge
• Eye Products Supplier Must Face DOJ's Kickbacks Suit
• AstraZeneca Expands Cancer Work With €62.6M Innate Stake
• Insurers Are Well-Positioned To Address Opioid Epidemic
• UK Biotech Orchard Primes $200M IPO Led By Goodwin
• Cravath Steers $2B J&J's Japanese Cosmetics Co. Buy
• Landmark Roundup Verdict Survives, But Cut Down By $211M
• Fed. Circ. Rejects Bid For PTAB Tribal Immunity Rehearing
• Medical Co. Inks $5.25M Deal To End FCA Accusations
• Labs Say UnitedHealth Can't Sue On State Fraud Claims
• Desmarais To Expand With New Bay Area Office
• Desmarais Adds Ex-Sidley Pair As Life Science Partners
• DePuy Can't Undermine $8.2M Patent Verdict, Court Told
• NECC Pharmacy Tech Testifies About Hijinks In Drug Lab
• Gov'ts Must Link Patient Data To Prescriptions In Opioid MDL
• Med Device Biz, Chinese Fintech Launch IPOs Totaling $141M
• Allergan Fights For Ropes & Gray Docs In Compounder IP Suit
• ​Takeaways From Senate Antitrust Enforcement Hearing
• Md. Asks Justices To Revive Generic-Drug Price-Gouging Law
• Fla. Pharmacy Hit With False Claims Suit Over Kickbacks
• Three Firms Guide Launch Of $508M In IPOs
• 8 Firms To Guide IPOs Surpassing $1.6B In Seesaw Market
• FDA Scraps Demands On Clinical Trial Falsity Reports
• Pharma Co. Wants Sex Drug Marketing Case Axed
• Pfizer Escapes Aussie Antitrust Watchdog's Lipitor Case
• Gov't Asks 9th Circ. To Revive New Birth Control Rules
• Cancer-Drug Maker Nabs $80M Financing, Names New CEO
• AbbVie Deal Clears 5th Humira Biosimilar To Launch In 2023
• Fake Patient Names Take Center Stage At 3rd NECC Trial
• J&J Unit Agrees To Risperdal Deal Ahead Of Philly Trial
• Need Litigation Finance? Don't Skip These 5 Steps
• Assessing Employment Rights Of NJ Medical Marijuana Users
• Medical Device Maker Sued Over 'Dangerous' Walking Boot
• ​Are You Ready For Your Congressional Investigation?
• Allergan Must Produce CEO's Tribal Patent Docs In MDL
• Teva Sues FDA Over New Stance On Generic-Drug Exclusivity
• Ex-J&J Employee Says She Was Fired For Whistleblowing
• Vitamin Distributor Can't Dodge $9M Default: Ill. High Court
• West Va. Jury Awards $1.2M In Pradaxa Blood Thinner Case
• Bristol-Myers, Pfizer's Blood Thinner IP Suit Axed Over Venue
• Eisai Downplayed Drug's 'Homicidal' Side Effects, FDA Says
• Casino Biz Prices $359M IPO, Biotech Firms Fall Short
• Miramar Finalizes Settlement Over Sientra Merger Suit
• McMillan Steers IAnthus, MPX In $683M Cannabis Co. Merger
• Jury Told Of Seized Drugs, Unsafe Workplace At NECC Trial
• LabMD Exec Sees FCA Suit Against Tiversa Trimmed
• Horizon Wants DLA Piper DQ'd In Hemophilia Treatment Row
• Glenmark Moves To Ax Zetia Pay-For-Delay Claims
• A New Framework For 'Blocking Patents' And Obviousness?
• Amgen Makes £50M Investment In Genetic Sequencing Co.
• Cravath, Faegre Steer Novartis' $2.1B Deal For Endocyte
• Aceto Execs Hit With Derivative Suit Over Stock Drop
• FTC On Ropes As Courts Wallop Suits Over Past Conduct
• A High Court Milestone Stirs Hope Of Gender Parity
• Cooley-Led Med Device Co. Prices $108M IPO Amid Volatility
• J&J Wants $20M Pa. Mesh Award Axed Over Alleged Time Bar
• 20 Drugmakers Must Face Generic Price-Fixing MDL
• Bayer Cholesterol Drug FCA Suit Survives Dismissal Bid
• 2 Biotech Cos. Launch IPOs Despite Erratic Market Conditions
• Calif. Tribes Become Latest To Bring Opioid Crisis Suits
• Imerys Fights Jurisdictional Ruling In NJ Asbestos Talc Row
• Lens Makers Look To Nix Price-Fixing Claims From MDL
• Co-Owner Of NY, NJ Pharmacies Charged With Tax Fraud
• Pfizer Can't Derail EpiPen Pay-For-Delay Discovery: 2nd Circ.
• Quick Chancery Appeal Sought For Rocky $4.8B Akorn Merger
• Policy Groups Back Teva In On-Sale Bar Case At High Court
• Teva, Eagle Fight To Block Generic Versions Of Chemo Drug
• Opioid MDL Gov'ts Must ID Prescriptions Or Limit Evidence
• Firms Win $3M In Fees In Hartig Product-Hopping Suit
• Trump's Rulemaking Agenda Aims To Cut $18B In Costs
• Pa. Justices Snub Preemption Fight Over Actiq Labeling
• Justices Asked If Sanctions Can Cover Presuit Actions
• FDA Warning Wire: E-Cig Juice Spiked With ED Drugs
• Cardiac Monitoring Patent Invalid Under Alice, Judge Rules
• Investors Sue Keryx Over $1.3B Merger With Akebia
• A Holistic Approach To Client Retention
• 1st Circ. Overturns Class Cert. In Allergan Price Fight
• Trevena Investors Sue Over Stock Drop Tied To Drug Trials
• Sinovac Investor Can't Halt Share Issue In Board Dispute
• The Path To Becoming A Supreme Court Advocate
• A Chat With Allens Pricing Chief Pier D'Angelo
• Ill. Health Insurance Nonprofits Sue Over Opioid Crisis
• Gender Disparity At The High Court: How Top Law Firms Measure Up
• Express Scripts Not Hurt By Alleged Breach, Pharmacies Say
• Opioid MDL Needs Gov't Docs To Advance, Drugmakers Say
• DOJ Charges Florida Men with $1B Telemedicine Fraud Scam
• Deals Rumor Mill: Innovent, Lime, HNA
• Abbott Says Former Exec Stole Marketing 'Playbook'
• $4.8B Akorn Ruling More Outlier Than Shift At Chancery
• 7th Circ. Revives Sex Harassment Witness' Firing Suit
• Ex-NECC Workers Blame Boss In Fraud Case
• Energy Drink Falsely Touts Nutritional Supplements, Suit Says
• Pharma Inventor's Ex-Wife Sues Him Over Patent Ownership
• 4 Key Takeaways As HHS Demands Drug Prices In TV Ads
• CFIUS Pilot Program: Immediate Investment Implications
• Supreme Court Women: A Vet & 1st-Timer Talk Gender Disparity
• Will The Future Of The Supreme Court Bar Be Female?
• Merck, Glenmark Tear Apart Zetia Pay-For-Delay MDL Claims
• 11 Firms To Lead IPOs Raising $1.8B Amid Market Volatility
• Health Hires: Insys, Ex-US Atty, Katten, Kasowitz, Dechert
• Sandoz Humira Biosimilar Set For 2023 After AbbVie Deal
• PTAB Axes Most Of Boston Scientific Stent Patent As Obvious
• Fed. Circ. Rules Teva's Copaxone Patents Are Invalid
• Liberty Mutual Shirking Painkiller Coverage, Pa. Suit Says
• Biotech Co. Slapped With Stock-Drop Suit Over Patent Failure
• Manning Gross, Kurowski Shultz To Join Forces In January
• The ABA Was Dead Wrong About Model Rule 8.4(g)
• K2M Shareholders Move To Block $1.4B Stryker Merger Vote
• Ranbaxy Abused 'First-To-File' For Heartburn Treatment: Suit
• 2 Fraud-Convicted Pharma Analysts Denied Acquittal Bids
• What Akorn Teaches Us About Delaware MAC Clauses
• Experts Highlight Real Estate's Key Role In Fla. Pot Market
• Impax Reverse Payment About Dodging Competition, FTC Told
• Ex-NECC Owner's Income Fair Game At Meningitis Trial
• Justices Urged To Ax Fed. Circ. Drug Patent Obviousness Test
• Drugmaker Urges Court To OK $3.8M Award In Supply Fight
• Drug Cos. Sold Contaminated Blood Pressure Meds, Suit Says
• Pfizer To Pay $700K In NY Penalties Over Drug Pricing Claims
• The Supreme Court Should Become Boring
• Pepper Hamilton Snags Patent Atty From Perkins Coie
• Sinovac Investors' Stock Injunction Bid Faces Skeptical Judge
• Laser Co. Zapped With Stock-Drop Suit Over Alleged Defects
• Cannabis Co. MedMen Picks Up PharmaCann In $682M Deal
• Back To School: BC's Kent Greenfield Talks Corporate Law
• Blue Cross Insurer, LabCorp Beat STD-Testing Antitrust Suit
• Cooley-Led Allogene Raises $324M After IPO Prices High
• The Rise In ESG Investing — And What Boards Can Do
• J&J Scores Trial Win In NJ Asbestos Talc Case
• Monsanto Nears $250M Slash Of Landmark Roundup Verdict
• Investor Says Teva Pharma Lied About Price-Hike Scheme
• J&J Concealed Talc Cancer Risk, NJ Jury Hears In Closings
• Duane Morris Adds Trade Secrets Buff From Knobbe Martens
• Trump Approves Prohibition On Pharmacy 'Gag Clauses'
• Fired Manager Says Abbott Refused To Accommodate Illness
• Deals Rumor Mill: Sears, WeWork, Bayer
• Real Estate Rumors: Alexandria, Atlantic Pacific, Fidelity
• Investors Want Sinovac Capital Frozen Before Caribbean Trial
• BioChemics Receiver Named To Help SEC Sniff Out $17M
• Teva Tells Justices AIA Hasn't Changed On-Sale Bar Meaning
• Fed. Circ. Upholds $20M Cialis Patent Verdict Against Lilly
• AbbVie Faces 2nd Investor Suit Over Humira Kickbacks
• Kavanaugh Cannot Be Compelled To Recuse Himself
• Gov't Brief In Fosamax Makes Strong Case For Reversal
• Eli Lilly Sues French Ex-Partner Over Patent Inventorship
• Opioid MDL Gov'ts Must Pinpoint Improper Prescriptions
• 'Chemo Brain' Should Expedite 2nd Roundup Trial, Judge Told
• FDA Warning Wire: McKesson Policy Lapses, Tainted Cat Food
• Boston Scientific Merger Trial Fast-Tracked In Chancery
• 450 Tribes Demand A 'Seat At The Table' In Opioid MDL
• Knowledge Management: An Unsung Hero Of Legal Innovation
• Justices Won't Tackle Jurisdiction Question In Lipitor Case
• Scooter Startup, Biotech Firm Launch IPOs Totaling $170M
• Gilead, Indian Generic Co. Drop Truvada Infringement Suit
• Fed. Circ. Upholds Decision Axing Roche TB Test Patent
• Adidas Taps Bayer US Legal Head For New General Counsel
• Doc Guilty Of Insider Trading On Wife's Ariad Drug Info
• SG To Argue At Supreme Court For Limiting On-Sale Bar
• Conn. Jury Hands Boehringer 3rd Straight Pradaxa Trial Win
• Ohio County's Opioid Bellwether Gets OK From Magistrate
• Outside Whistleblowers Key To $625M Amerisource FCA Deal
• 6 Firms To Guide 5 IPOs Exceeding $1B Led By Lithium Co.
• Ariad Insider Trading Case Now In Boston Jury's Hands
• Westminster, CVS Sold Bad Thyroid Tablets, Class Suit Says
• Illumina Investors File Class Action Over $6.6B Stock Drop
• Allergan's Sanctions Bill 'Unreasonable,' Imprimis Says
• B. Braun Settles IV Tylenol IP Row After Losing Venue Fight
• Accutane Ruling Raises Bar For Garden State Labeling Claims
• PTAB Invalidates Patent For Biogen's Cancer Drug Rituxan
• What New Calif. Law Means For Connected Medical Devices
• Jury Clears Bard In Third IVC Bellwether Trial
• Purdue Must Face Trimmed Suit Over Opioid Marketing
• Cancer Test Provider Raises $238M In IPO As Shares Soar
• Insurer Owed Nobilis Defense Of Stock Drop Suits: Judge
• Biopharma Co. Sued After Leukemia Treatment Trial Fails
• IQVIA Can't Nix Counterclaims In Trade Secrets Suit
• 3rd Circ. Won't Rehear Talc Suit That Could Move To Calif.
• Intuitive Investors Get $42.5M Deal With Bargain Attys' Fees
• 1st Circ. Won't Rehear Novartis Gleevec Antitrust Suit
• Akorn Could Alter 'Material Adverse Effect' Law In Delaware
• Athena Asks Fed. Circ. To Revive Nixed Biotech Patent
• Disbarred Atty, Ex-Clients Ink $19M Deal In Fen-Phen Case
• J&J Unit Strikes $3.7B Hepatitis B Gene Therapy Deal
• Bard Says Vein Filter Risks Reasonable As Trial Wraps
• J&J Expert: Mesothelioma In Women Rarely Due To Asbestos​​​​​​​
• Senate Sends Sweeping Opioid Legislation To Trump's Desk
• Fla. Judge To Block Medical Marijuana Rules
• FDA Petition-Shaming Plan Gives Ammo To Antitrust Suits
• ActiveCare Ch. 11 Sale OK'd With Liability Concerns Resolved
• 4 Firms Break From Pack In Scorching September For IPOs
• Ill. Wants Sterigenics Plant Closed Amid Cancer Concerns
• Talc From EBay Wrongly Kept Out Of P&G Trial, NJ Court Told
• Calif. Man Says Monsanto Can't Get Redo After $298M Win
• PTAB Upholds 2 Genentech Herceptin Patents, Invalidates 1
• NJ Justices Say Garden State Law Topples Accutane Cases
• Skip The New 'Civility Courses' And Think Like A Lawyer
• EHealthline Appeals OK Of $3.5M Award To 9th Circ.
• SEC Enforcement Co-Head Sees Year-End Stats As Overrated
• J&J Suit Over Talc-Cancer Link Sent Back To Pa. State Court
• Deals Rumor Mill: Marathon Oil, Peabody Energy, Atai
• US, China Still Sizing Each Other Up In WTO Tariff Dispute
• Why Law Firms Should Monitor The Dark Web
• Ex-Abbott Researcher Says 'Erroneous' Law Sank FCA Claims
• Claims Trimmed In Bard Vein Filter Bellwether Home Stretch
• Anti-Monopoly Group Wants 1st Circ. To Rehear Novartis Case
• Pfizer, Hospira Urge Final Nix Of Suit Over Faulty Pumps
• Dentons Poaches Trio Of Perkins Coie Patent Litigators
• 2 Cooley-Led Biotech Startups Launch IPOs Totaling $342M
• Ligand Asks Chancery To Toss Costly Formula Error Suit
• ITC Launches Probe Into ResMed Rival's Sleep Mask Imports
• FDA Focus: What Mintz's Practice Chair Is Watching
• Baker Donelson DQ'd In BCBS Antitrust Row Against Ex-Client
• HHS' Acting GC Under Obama Returns To Zuckerman Spaeder
• Fed. Circ. Nixes PTAB Remand In Settled Eye Drug Case
• Does Rule 45 Protect Nonparties From Undue Burden?
• Consumers Seek Sanctions For Mylan In EpiPen Pricing Suit
• Abbott, Distributor Settle 'Gray Market' Test Strip TM Fight
• No Injury Means No Standing For A Talc Plaintiff
• O'Melveny Adds Ex-Paul Hastings IP Partner
• Commerce Ordered To Take 3rd Look At Duties On Radiators
• Amerisource Inks $625M FCA Deal In 'Sham Pharmacy' Row
• Xtampza Not Infringing 2 OxyContin Patents, Judge Says
• Fed. Circ. Upholds Re-Exam Ax Of Athlete Endurance Patents
• Doctor's Duplicative FCA Suit Against MedImmune Dismissed
• Lion Biotech Strikes $3.3M Deal In Stock-Drop Suit
• Life Science Co. Gets $150M Funding From TPG Sixth Street
• Osmotica, Anaplan, Livent IPOs Worth $722M Led By 3 Firms
• Justices Won't Review Janssen's Liability For Risperdal Death
• Doc Traded On Wife's Cancer Drug Knowledge, Jury Hears
• FDA Will Update Cybersecurity Guidance For Medical Devices
• Forbion's 4th Life Sciences Fund Hits $417M In Final Close
• Chancery Lets Fresenius Ditch $4.3B Akorn Deal